Longeveron (LGVN)

• Market cap: $19.5M
• 1 day: -1.52%
• 5 days: 4.84%
• 1 month: -9.72%
• 3 months: -20.73%
• 6 months: -30.11%
• Year to date: -27.37%
• 1 year: -51.67%
• 5 years: -98.25%
• 10 years: -98.25%
• Sector: Healthcare
• Industry: Biotechnology

About: Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty.

Employees: 25

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

0.13% more ownership

Funds ownership: 3.65% [Q4 2024] → 3.78% (+0.13%) [Q1 2025]

0% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 5

6% less capital invested

Capital invested by funds: $844K [Q4 2024] → $791K (-$53.8K) [Q1 2025]

13% less funds holding

Funds holding: 23 [Q4 2024] → 20 (-3) [Q1 2025]

60% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 5

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $10 669% upside
• Avg. target: $10 669% upside
• High target: $10 669% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Raghuram Selvaraju

669% upside $10

Buy Reiterated

21 Mar 2025